Skip to content

Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy.

Sep 2026 · Science · Vol 393 6818, pp. eaej5896 · 1 citation · 99 references
Medicine

TL;DR

Through high-throughput screening, this work identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF.

Abstract

Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration-approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cell (iPSC)-based platform. Through high-throughput screening, we identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF. Mechanistic studies revealed an atypical adenosine receptor (AR)-dependent signaling pathway in which AR subtypes converge on Gβγ (the βγ subunits of heterotrimeric GTP-binding proteins) to activate phosphoinositide 3-kinase (PI3K)-AKT and yes-associated protein (YAP). CGS suppressed this signaling axis, thereby reducing fibrotic gene expression and fibroblast activation. These findings establish AR-driven Gβγ signaling as a potential therapeutic target for cardiac fibrosis.

View source

Similar papers

Review Open access Oct 2026

Irisin/Integrin αVβ5/AMPK Signaling in Cardiac Fibrosis: Molecular Mechanisms and Therapeutic Potential

Cardiac fibrosis is a major pathological feature of several cardiovascular diseases and is characterized by excessive extracellular matrix deposition, leading to ventricular stiffening, impaired cardiac function, and ultimately heart failure. Despite its substantial clinical burden, therapies specifically targeting the...

Darío Cañate Cañate, P. Araos, S. Bolívar-González · 0 citations
Review Open access Sep 2026

Cardiac Fibrosis as a Dynamic Therapeutic Target: Overcoming Translational Barriers to Antifibrotic Therapy.

Cardiac fibrosis is a central feature of many cardiovascular diseases, contributing to myocardial stiffening, electrical dysfunction, and progression to heart failure. Despite its clinical importance, no therapy directly targeting myocardial fibrosis is currently established in practice. Advances in the understanding o...

Shuchishmita Maitra, X. Wehrens, Svetlana Reilly · 0 citations
Open access Aug 2026

SerpinA3 is an Endogenous TGF‐β Receptor Antagonist that Attenuates Cardiac Fibroblast Activation and Fibrotic Remodeling

SerpinA3 functions as an endogenous inhibitor of TGF‐β signaling that restrains cardiac fibroblast activation and fibrotic remodeling and is identified as a promising therapeutic target for HF associated with pathological fibrosis.

Hui Wang, Jie Cui, Chun-Lu Huang et al. · 0 citations
Open access Aug 2026

Glucose-dependent insulinotropic polypeptide receptor agonism improves heart failure with antifibrosis through Akt-dependent nitric oxide signaling

DA-GIP suppresses cardiac fibroblast activity through Akt-dependent eNOS activation and subsequent NO production, thereby improving cardiac remodeling and function in experimental heart failure.

Ting-Wei Lee, Ting-I Lee, Satoshi Higa et al. · 0 citations
Review Sep 2026

New approach methodologies: drug screening platform to identify antifibrotic compounds.

This high-throughput screening system uses human reporter induced pluripotent stem cell-derived cardiac fibroblasts to identify initial hits with potential antifibrotic effects, followed by counter-screening using iPS cell-derived cardiomyocytes to exclude compounds with potential cardiotoxicity.

Hao Zhang, Lu Ren, Rihua Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.